R&D A new approach to drug design: Restoring the effectiveness o... None of us are unaware of the very real danger of ‘superbugs’ – only last month, the hospita
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
